Education
About Us
Working with TipRanks
Follow Us
Traws Pharma (TRAW)
NASDAQ:TRAW
Total Valuation
Traws Pharma has a market cap or net worth of $9.18M. The enterprise value is -$12.10M.
Market Cap$9.18M
Enterprise Value-$12.10M
Share Statistics
Traws Pharma has 5,564,315 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding5,564,315
Owned by Insiders52.65%
Owned by Institutions30.87%
Financial Efficiency
Traws Pharma’s return on equity (ROE) is 5.26 and return on invested capital (ROIC) is -1060.20%.
Return on Equity (ROE)5.26
Return on Assets (ROA)-6.67
Return on Invested Capital (ROIC)-1060.20%
Return on Capital Employed (ROCE)-10.60
Revenue Per Employee37.67K
Profits Per Employee-27.75M
Employee Count6
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Traws Pharma is -1.35. Traws Pharma’s PEG ratio is 0.01.
PE Ratio-1.35
PS Ratio0.00
PB Ratio-1.33
Price to Fair Value-7.11
Price to FCF-0.31
Price to Operating Cash Flow-1.41
PEG Ratio0.01
Income Statement
In the last 12 months, Traws Pharma had revenue of 226.00K and earned -166.52M in profits. Earnings per share was -6.58.
Revenue226.00K
Gross Profit214.00K
Operating Income-142.37M
Pretax Income-166.52M
Net Income-166.52M
EBITDA-24.90M
Earnings Per Share (EPS)-6.58
Cash Flow
In the last 12 months, operating cash flow was -30.80M and capital expenditures 0.00, giving a free cash flow of -30.80M billion.
Operating Cash Flow-30.80M
Free Cash Flow-30.80M
Free Cash Flow per Share-5.54
Dividends & Yields
Traws Pharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.11
52-Week Price Change-88.66%
50-Day Moving Average1.61
200-Day Moving Average4.84
Relative Strength Index (RSI)60.13
Average Volume (3m)2.32M
Important Dates
Traws Pharma upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 15, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Traws Pharma as a current ratio of 2.16, with Debt / Equity ratio of 0.00%
Current Ratio2.16
Quick Ratio2.16
Debt to Market Cap0.00
Net Debt to EBITDA0.86
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Traws Pharma has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Traws Pharma EV to EBITDA ratio is -8.17, with an EV/FCF ratio of -6.83.
EV to Sales900.10
EV to EBITDA-8.17
EV to Free Cash Flow-6.83
EV to Operating Cash Flow-6.83
Balance Sheet
Traws Pharma has $15.94M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$15.94M billion.
Cash & Marketable Securities$15.94M
Total Debt$0.00
Net Cash-$15.94M
Net Cash Per Share-$2.86
Tangible Book Value Per Share-$1.25
Margins
Gross margin is 95.58%, with operating margin of -62997.35%, and net profit margin of -73682.74%.
Gross Margin95.58%
Operating Margin-62997.35%
Pretax Margin-73682.74%
Net Profit Margin-73682.74%
EBITDA Margin-11016.81%
EBIT Margin-11022.12%
Analyst Forecast
The average price target for Traws Pharma is $6.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$6.00
Price Target Upside261.45% Upside
Analyst ConsensusModerate Buy
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast-404.67%